ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-02-12

Last Posted Date: 2021-02-11

Lead Sponsor: AbbVie

Target Recruit Count: 401

Registration Number: NCT02362074

Locations: 🇨🇦
Drs. M & W Teo Inc. /ID# 148641, Penticton, British Columbia, Canada
🇨🇦
Kur, Vancouver, CA /ID# 135371, Vancouver, British Columbia, Canada
🇨🇦
Nexus Clinical Research /ID# 135411, St. John's, Newfoundland and Labrador, Canada

and more 29 locations

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: Sofosbuvir
Drug: Ribavirin

First Posted Date: 2015-02-05

Last Posted Date: 2017-12-20

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT02356562

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Phase 2

Completed

Conditions: Psoriatic Arthritis

Interventions: Biological: adalimumab
Biological: ABT-122

First Posted Date: 2015-01-28

Last Posted Date: 2017-08-04

Lead Sponsor: AbbVie

Target Recruit Count: 240

Registration Number: NCT02349451

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: Lomustine
Drug: Depatuxizumab mafodotin
Drug: Temozolomide

First Posted Date: 2015-01-22

Last Posted Date: 2020-05-22

Lead Sponsor: AbbVie

Target Recruit Count: 266

Registration Number: NCT02343406

Locations: 🇫🇷
Hopital Pitie Salpetriere /ID# 145887, Paris, France
🇮🇹
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy
🇫🇷
CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France

and more 99 locations

Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Adalimumab

First Posted Date: 2015-01-07

Last Posted Date: 2019-01-15

Lead Sponsor: AbbVie

Target Recruit Count: 201

Registration Number: NCT02333383

Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA

Withdrawn

Conditions: Rheumatoid Arthritis

First Posted Date: 2014-12-23

Last Posted Date: 2016-02-19

Lead Sponsor: AbbVie

Registration Number: NCT02322723

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Untreated Metastatic Colorectal Cancer

Interventions: Drug: Placebo
Drug: Veliparib
Drug: FOLFIRI
Drug: Modified FOLFIRI
Drug: Bevacizumab
Drug: Fluorouracil infusion

First Posted Date: 2014-12-03

Last Posted Date: 2018-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 130

Registration Number: NCT02305758

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: ABT-493
Drug: ABT-530

First Posted Date: 2014-11-21

Last Posted Date: 2015-10-21

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT02296905

Locations: 🇳🇿
Site Reference ID/Investigator# 130590, Grafton, New Zealand
🇺🇸
Site Reference ID/Investigator# 130588, San Antonio, Texas, United States
🇺🇸
Site Reference ID/Investigator# 130589, Miami, Florida, United States

and more 1 locations

A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C Virus Infection

Interventions: Drug: OBV/PTV/r
Drug: Sofosbuvir
Drug: Ribavirin (RBV)

First Posted Date: 2014-11-17

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 70

Registration Number: NCT02292719

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Veliparib
Drug: Etoposide
Drug: Placebo

First Posted Date: 2014-11-13

Last Posted Date: 2020-05-14

Lead Sponsor: AbbVie

Target Recruit Count: 221

Registration Number: NCT02289690

Locations: 🇨🇿
Vitkovicka nemocnice a. s. /ID# 149839, Ostrava, Czechia
🇰🇷
Chonnam National University Hwasun Hospital /ID# 153188, Jeonnam, Korea, Republic of
🇺🇸
Georgia Regents University /ID# 148567, Augusta, Georgia, United States

and more 59 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy